Ipsen SA

99,13

08-апреля-25 11:29:55

15 мин. задержка

Акции

+1,25

+1,28%

Сегодняшний диапазон

98,05 - 100,80

ISIN

FR0010259150

Источник

Cboe

Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

04 сен 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

13 авг 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

06 авг 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

05 авг 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

30 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

26 июл 2024 06:46:22 Источник Nasdaq GlobeNewswire
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

25 июл 2024 08:18:23 Источник Nasdaq GlobeNewswire
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

25 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

25 июл 2024 00:58:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

23 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

11 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

09 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Half-year statement of IPSEN liquidity agreement - 2024 06 30

08 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

02 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

25 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

18 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

11 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.